INTRODUCTION
In 2017, it is estimated that 26,070 patients will be diagnosed with a malignant primary brain tumor in the United States, with more than half having the diagnosis of glioblastoma (GBM). 1 Magnetic resonance imaging (MRI) is a widely utilized examination in the diagnosis and post-treatment management of patients with glioblastoma; standard modalities available from any clinical MRI scanner, including T1, T2, T2-FLAIR, and T1-contrast-enhanced (T1CE) sequences, provide critical clinical information. In the last decade, advanced imaging modalities are increasingly utilized to further characterize glioblastomas. These include multi-parametric MRI sequences, such as dynamic contrast enhancement (DCE), dynamic susceptibility contrast (DSC), diffusion tensor imaging (DTI), functional imaging, and spectroscopy (MRS), to further characterize glioblastomas, and significant efforts are ongoing to implement these advanced imaging modalities into improved clinical workflows and personalized therapy approaches. A contemporary review of standard and advanced MR imaging in clinical neuro-oncologic practice is presented.
Initial diagnosis and surgical management
Most patients with glioblastoma undergo computed tomography of the brain upon initial presentation. Once a mass is identified and hemorrhage is excluded, a contrastenhanced MRI is typically ordered, with standard T1, T2, FLAIR, and contrast-enhanced T1 (T1CE) sequences. 2, 3 Many institutions will also capture gradient echo and diffusion sequences. Maximal safe debulking surgery is recommended as the initial standard of care. Neurosurgeons will often utilize high-resolution MRI (0.5 -1.2mm slice thickness) for surgical planning and intraoperative guidance, as well as to make the determination of how aggressively to resect based on risk of toxicity to nearby eloquent regions. 4 Standard imaging also can identify other important characteristics of the mass in situ, including the amount of necrosis, compression of the surrounding normal tissue, and midline deviation.
A recent meta-analysis of over 40,000 glioblastoma patients demonstrated that grosstotal resection was associated with improved survival as compared to subtotal resection. 5 Historically, the determination of gross-total resection was made in the operating room by the neurosurgeon. However, in the modern era, the practice of obtaining a postoperative contrast-enhanced MRI within 24-48 hours of surgery has become routine after publication of a study showing that radiological determination of the extent of resection via MRI had prognostic significance. 6 Several series have attempted to quantify a threshold value for the extent of resection as a guide for neurosurgeons, utilizing the amount or enhancing tumor present in the preoperative and post-operative T1CE images. These series report thresholds ranging from 70% to 100% [7] [8] [9] , with the caveats that they were obtained retrospectively. 15 and can help distinguish between post-operative vascular damage and residual enhancing tumor. 16 Dynamic contrast-enhanced (DCE) sequences in the preoperative setting measure pharmacokinetic parameters of contrast uptake, which may be associated with early disease progression and survival. 17 Dynamic susceptibility contrast (DSC) MR imaging may be helpful in preoperative diagnosis 18 of malignant lesions. Imaging features extracted from standard and advanced preoperative MR sequences can predict survival, molecular subtype, and mutational status in glioblastoma, 19, 20 potentially enhancing the set of imaging biomarkers available to clinicians.
Post-operative imaging and radiation planning
After maximal safe resection, which is evaluated on immediate post-operative MRI, the standard of care for patients with glioblastoma is chemoradiation with concurrent temozolomide, after the results of a large randomized Phase III trial. 21 Typically, chemoradiation begins 3-6 weeks after surgery to allow JHN JOURNAL Glioblastoma MRI Review along with fractional anisotropy measurements from diffusion images, ADC values may be associated with poor response to treatment and worse survival among high grade glioma patients. 29 Diffusion and perfusion parameters, when combined with standard MR sequences, may allow radiation oncologists to better characterize the highest-risk regions to include in high-dose target volumes, utilizing macroscopically visible features 30 as well as radiomic features. 31 Voxel-based MR spectroscopy (MRS) and whole-brain spectroscopic MRI (sMRI) may identify regions of tumor infiltration and areas at high risk of recurrence; 32 regions with metabolic abnormalities on sMRI are correlated with intraoperative tissue samples showing increased immunohistochemical staining for neoplastic cells. 33 
Response Assessment
As demonstrated at any multidisciplinary tumor board, imaging is of utmost importance in the interpretation of the response to treatment in glioblastoma. The first widelyadopted set of guidelines for standardizing the assessment of treatment response that utilized MR imaging was the Macdonald criteria, 34 which used clinical parameters in conjunction with imaging measurements to classify responses into four broad categories (complete response, partial response, stable disease, and progressive disease).
MR imaging to define the at risk target volumes and organs at risk.
It is common to identify shifting of brain parenchyma on planning CT in the weeks after craniotomy as the normal brain tissue expands to fill the space taken out by the tumor. One study demonstrated a 4mm shift in the position of the treatment isocenter between CT and MRI-based target delineation, 25 even with only a few days between studies. The magnitude of the shift can be several centimeters, resulting in inaccurate registration between post-operative MRI and simulation CT. Many institutions have begun the practice of obtaining repeat MRI at the time of simulation to better characterize the soft tissues for target delineation.
Advanced imaging at this time point may play a role in radiation planning. A Polish study demonstrated the discordance between gross tumor volume (GTVs) delineated from MRI as compared to 18F-fluoroethylthyrosine-PET (FET-PET), a functional imaging modality; FET-PET was better associated with the site of eventual failure, suggesting that traditional target volumes may not be adequate. 26 ADC maps generated from diffusion imaging can identify areas of restricted diffusion that may predict for areas of eventual recurrence with high concordance; 27, 28 for adequate post-operative recovery. Radiotherapy planning includes registration (aka "fusion") of the post-operative MRI (T1CE and FLAIR sequences) with the planning simulation CT, which allows for delineation of the FLAIR abnormality and residual enhancement in treatment planning. Guidelines for these delineations exist, but substantial variation is observed among practitioners from different cooperative groups (e.g., RTOG 22 vs. EORTC 23 ), and even among practitioners from one country, 24 but all utilize post-operative Figure 11 .
Pre-and immediate post-operative (at 24 hours) axial t1CE weighted images. On post-operative image, there is minimal residual enhancement particularly along the medial aspects of the surgical site, concerning for minimal residual tumor. Majority of the hyperintense signal in the right parieto-occipital region is related to blood post-operative blood products. T1CE, T1-weighted contrast-enhanced. Dynamic susceptibility contrast (DSC) perfusion weighted image. There is increase in rCBV (relative cerebral blood volume) in the region of right frontal mass (Figures 1-4) , a finding favoring high grade neoplasm. Tractography image demonstrates the intimate relationship of right frontal mass with the corticospinal tract (blue colored fibers).
Challenges and limitations of the Macdonald criteria became apparent as imaging modalities revealed more details about gliomas and their response to treatment. The importance of noncontrast-enhancing regions of abnormality has become better understood; for example, changes in the volume of Single voxel MR spectroscopy at long TE (288 ms) acquired through the right temporoparietal region mass with imaging appearance compatible with glial neoplasm. There is markedly elevated choline (resonates at 3.2 ppm) with markedly decreased NAA (resonates at 2 ppm), a finding consistent with high grade glial neoplasm. MR, magnetic resonance. Follow up of a case of glioblastoma on therapy. Axial FLAIR weighted image demonstrates a large area of infiltrating hyperintense signal abnormality in right temporo-occipital region, with associated mass effect and leftwards shift of midline. FLAIR, fluid-attenuated inversion recovery.
immunotherapy response assessment in neuro-oncology (iRANO) criteria, 42 which attempted to provide standardized guidelines for the determination of tumor progression in the setting of immunerelated therapy.
MRI imaging features have the potential to predict treatment response to specific modalities of treatment. Relative cerebral blood volume and dynamics parameters (K¬trans and Ve), measured by perfusion-weighted MR imaging and other features may predict treatment response to standard chemoradiation and VEGF inhibitors, [43] [44] [45] prior to initiation of therapy. Radiomic features derived from these images have been shown to have predictive value as well. 46 
CONCLUSIONS
The volume of medical imaging data continues to grow at an exponential rate. As MR imaging becomes more cost-effective and the adoption of advanced MR modalities becomes more widespread, it will become more critical than ever to incorporate advanced imaging and the power of large datasets into the management of glioblastoma. We anticipate that these changes will include not only the utilization of new MR sequences but also novel image analysis techniques, including radiomic analysis, to better drive treatment decisionmaking, with the goal of improving clinical outcomes in glioblastoma.
is most commonly observed in patients whose tumors harbored a methylated MGMT promoter region, 36 and makes accurate assessment of response difficult, especially in the setting of clinical trials attempting to answer the question of efficacy of novel treatment regimens. Some medications, including anti-angiogenic drugs and immunologic agents, elicit unique radiographic changes which may mask accurate response assessment as well.
These limitations, among others, led to the development of a new set of guidelines developed by the Response Assessment in Neuro-Oncology (RANO) working group, 37 which incorporates more information from MR imaging, including FLAIR sequence changes, into the objective assessment. The RANO criteria have been incorporated into clinical trials and daily clinical practice, allowing better applesto-apples comparisons. 38 Clinical trials in the last decade demonstrated the benefit of bevacizumab, an anti-angiogenic monoclonal antibody, in recurrent glioblastoma. 39 The radiographic appearance of malignant gliomas changes dramatically after treatment with bevacizumab as a result of changes in vessel permeability and contrast dynamics. 40 Initial studies showed the difficulty in distinguishing these radiographic changes from true tumor effect; the temporal dynamics were also unclear. 41 These issues led to the development of the hyperintensity on post-treatment FLAIR imaging, relative to baseline, are correlated with improved survival. 35 Furthermore, some glioblastomas demonstrate imaging changes consistent with progression under the Macdonald criteria, but upon repeat surgical intervention, viable tumor cannot be identified in the resection specimen, suggesting that the adjuvant treatment may actually be having a positive effect that eludes detection on conventional imaging. This finding, termed "pseudoprogression," Axial post-contrast T1 (T1CE) images at 8 months. There is a large heterogeneously enhancing mass in the right parieto-occipital region at the operative site. There is interval development of multiple enhancing nodules along the ependymal surface of ventricles, particularly along the right frontal and temporal horn, and roof of fourth ventricles. These findings are compatible with tumor progression. T1CE, T1-weighted contrast-enhanced. On dynamic susceptibility contrast (DSC) perfusion weighted imaging, the area of signal abnormality predominantly demonstrates low relative cerebral blood volumes. The overall findings were consistent with pseudoprogression.
